Probably every investor interested in biotech knows all of the challenges facing Gilead Sciences (NASDAQ: GILD). Its once high-flying stock has been beaten down over the last couple of years as sales plunged for its hepatitis C franchise.
However, over the last month, Gilead stock has begun a tentative but distinct rebound. Is now the time to buy Gilead Sciences stock? These three charts show why the answer is “yes.”
Image source: Getty Images.